Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2023-07-14 Interim / Quarterly Rep…
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT 1 JANUARI – 30 JUNI 2023' (Interim Report 1 January – 30 June 2023). It contains comprehensive financial statements, including income statements, cash flow analysis, balance sheet data, and management commentary regarding the company's performance for the first half of the year. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2023
2023-07-14 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT 1 JANUARY – 30 JUNE 2023' and contains comprehensive financial statements, including net sales, operating profit/loss, cash flow, and balance sheet data for the specified period. It also includes management commentary, business updates, and shareholder information. It is a full interim financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). H1 2023
2023-07-14 English
Episurf Medical: Strategiuppdatering för att ta nästa kommersiella steg och förbättra finansiellt resultat
Regulatory Filings Classification · 1% confidence The document is a press release from Episurf Medical announcing a 'Strategiuppdatering' (Strategy Update). It details operational changes, cost reductions, increased focus on the US market, and a shift to a distributor model. It also mentions the expected impact on Q2 2023 results (one-time cost) and the sufficiency of current financing. Crucially, the final paragraph states: 'Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande kl. 08.15 den 14 juli 2023.' This indicates a mandatory regulatory disclosure concerning significant business strategy changes. Since it is not a formal financial report (10-K, IR, ER) but a strategic announcement required for public disclosure, it fits best under the general 'Regulatory Filings' category (RNS) or potentially a specific announcement type if one were closer. Given the content is a strategic business update rather than a specific transaction (like DIRS, DIV, CAP) or a formal report release (RPA), RNS serves as the most appropriate general regulatory disclosure category for significant, non-standard announcements under this schema. It is not a Call Transcript (CT), Earnings Release (ER), or Interim Report (IR).
2023-07-14 Swedish
Episurf Medical: Strategy update to take the next commercial steps and improve financial results
Board/Management Information Classification · 1% confidence The document is an announcement titled "Episurf Medical: Strategy update to take the next commercial steps and improve financial results." It details strategic shifts, operational measures, cost reductions, and future product launch plans (US market focus, distributor model). It concludes with a statement about information submission pursuant to the EU Market Abuse Regulation, dated July 14, 2023. This content is a high-level strategic update and financial outlook announcement, not a full financial report (10-K or IR), a transcript (CT), or a formal dividend/share change notice. It most closely aligns with an Earnings Release (ER) which often includes strategic commentary alongside initial results/outlook, or potentially a Regulatory Filing (RNS) if it doesn't fit the ER mold perfectly. Given the focus on strategic direction, cost improvements, and outlook following a period, it functions similarly to an Earnings Release, even if specific quarterly figures are minimal (it mentions a one-time expense in Q2 2023 report). However, since it is primarily a strategic update rather than a formal release of period results (which would typically be an ER or IR), and it is a specific corporate announcement, the most appropriate general category for significant, non-standard corporate news that isn't a core financial report is often RNS, or if it contains management discussion about performance/outlook, ER. Since it discusses financial improvement and operational changes, ER is a strong candidate, but it lacks the typical structure of a formal earnings release (e.g., detailed P&L/Balance Sheet highlights). Given the nature of strategic corporate news that impacts future performance, and the lack of a specific category for 'Strategy Update', RNS (Regulatory Filings/General Announcement) is the safest classification, although ER is plausible if this is the accompanying press release for quarterly results not fully detailed here. Reviewing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document focuses heavily on strategy and cost-cutting, which often accompanies ERs. Since it is a formal announcement of material strategic change, RNS is the most robust fallback for non-standard material news. I will classify it as RNS as it is a broad regulatory announcement of material strategic change.
2023-07-14 English
Förändring av antalet aktier och röster i Episurf Medical
Share Issue/Capital Change Classification · 1% confidence The document text is a short announcement in Swedish regarding a change in the number of shares and votes following the exercise of stock options (teckningsoptioner). It explicitly states the increase in B-shares and the total resulting share count. This type of announcement, detailing changes in the capital structure due to option conversion or new share issuance, directly corresponds to the 'Share Issue/Capital Change' category. The filing is short and contains the core information, making it a direct report rather than an announcement of a report. Therefore, the appropriate code is SHA.
2023-06-30 Swedish
Change in number of shares and votes in Episurf Medical
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly details a 'Change in number of shares and votes' due to the exercise of warrants. It states the total number of shares and votes has increased. This directly relates to a change in the company's capital structure or share count. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate classification for announcements detailing changes in the total number of outstanding shares, even if triggered by warrant conversion.
2023-06-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.